Status:
COMPLETED
Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Pneumonia, Viral
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Severe Acute Respiratory Syndrome (SARS) SARS-CoV-2, name of the Coronavirus Group of international Committee on taxonomy of viruses, is an emerging virus from the family of coronaviridae, responsible...
Eligibility Criteria
Inclusion
- Patient with COVID-19 pneumonia
- Positive PCR for COVID-19 on respiratory sample (saliva, nasopharyngeal, bronchial, tracheal aspiration or LBA)
- Having required hospitalization in the pulmonology service, intensive care in pneumology or resuscitation service at the Toulouse University Hospital
- Saturation \<94% in ambient air at diagnosis
- Patient having a chest CT-scan proving pneumonia during his hospitalization
- Patient ≥ 18 years old
- Patient who has given written consent to participate in the study
Exclusion
- Patient hospitalized for pneumonia not documented by a chest CT-scan
- Patient with negative COVID PCR
- Patient known before the episode of COVID-19 pneumonia for a respiratory or cardiac pathology which can lead in itself to an alteration of gas exchanges
- Patient under curators / guardianship
- Pregnant patient
- Minor patient
- Absence of consent for participation in the study
- Medical condition that does not allow for pulmonary function test
Key Trial Info
Start Date :
May 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 29 2021
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT04422613
Start Date
May 28 2020
End Date
October 29 2021
Last Update
November 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Toulouse
Toulouse, France, 31000